Sigma 1受体配体SA4503与PRE084在rd10视网膜色素变性小鼠模型中的比较
该研究在661W细胞和rd10视网膜色素变性(RP)小鼠模型中比较了SA4503、PRE084与(+)-PTZ三种Sigma 1受体配体的视网膜保护作用;体外实验中三者均改善细胞活力、减轻氧化应激并上调Nrf2、Nqo1和Cat表达,但体内仅(+)-PTZ改善视力、外层视网膜厚度及明适应a、b波反应并显著增加光感受器核数量,SA4503与PRE084未显示可比保护作用。
要点
- 体外实验中SA4503、PRE084与(+)-PTZ均改善661W细胞活力并上调Nrf2、Nqo1和Cat表达。
- rd10小鼠体内仅(+)-PTZ改善视力、外层视网膜厚度及明适应a、b波反应。
- SA4503与PRE084处理组光感受器核数量约11/100 µm,与未处理组无显著差异。
核心结论
- 三种配体在体外均显示激活Sigma 1受体的潜力,但仅(+)-PTZ在rd10模型中提供视网膜神经保护,三者体内保护作用差异显著。
研究设计与样本
- 研究使用661W细胞进行体外实验,并在rd10视网膜色素变性小鼠模型中进行体内实验。
- rd10小鼠分别接受SA4503(1 mg/kg)、PRE084(0.5 mg/kg)或(+)-PTZ(0.5 mg/kg)处理。
- 体内评估指标包括视力、视网膜结构和视网膜电生理功能,并进行了组织学检查。
主要发现
- SA4503和PRE084与(+)-PTZ类似,可改善细胞活力、减轻氧化应激并增加Nrf2、Nqo1和Cat表达。
- (+)-PTZ处理改善rd10小鼠视力、增加外层视网膜厚度并改善明适应a波和b波反应,SA4503或PRE084未显示这些效果。
- SA4503和PRE084处理组光感受器核数量约11/100 µm,与未处理rd10小鼠无显著差异,(+)-PTZ处理组约22/100 µm,显著更多。
关键数值与推荐
- SA4503给药剂量为1 mg/kg,PRE084和(+)-PTZ给药剂量均为0.5 mg/kg。
- SA4503和PRE084处理组光感受器核数量约11/100 µm,与未处理组无显著差异。
- (+)-PTZ处理组光感受器核数量约22/100 µm,显著多于未处理组。
临床怎么用
- 结果提示Sigma 1受体配体的视网膜神经保护作用不能由受体激活潜力简单外推,需逐个配体进行体内验证。
- (+)-PTZ在rd10模型中显示的结构与功能保护结果为后续候选配体筛选提供参考。
局限性
- 研究仅基于661W细胞和rd10小鼠模型,结论向其他RP模型或人类外推受限。
- 原文未报告样本量、具体统计P值及置信区间等信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Sigma 1 receptor is a novel therapeutic target for retinal disease. Its activation, using a high-affinity, high-specificity ligand (+)-pentazocine ((+)-PTZ), rescues photoreceptor cells in the rd10 mouse model of RP. Here, we asked whether the robust retinal neuroprotective properties of (+)-PTZ are generalizable to SA4503 and PRE084, two other high-affinity sigma 1 receptor ligands. METHODS: We treated 661W cells with SA4503 or PRE084. Cell viability, oxidative stress, and expression of Nrf2 and NRF2-regulated antioxidant genes (Nqo1, Cat, and Sod1) were assessed. Rd10 mice were administered SA4503 (1 mg/kg), PRE084 (0.5 mg/kg), or (+)-PTZ (0.5 mg/kg). Visual acuity, retinal architecture, and retinal electrophysiologic function were measured in vivo and retinal structure was assessed histologically. RESULTS: Similar to (+)-PTZ, SA4503 and PRE084 improved cell viability, attenuated oxidative stress, and increased Nrf2, Nqo1 and Cat expression. Although treatment of rd10 mice with (+)-PTZ improved visual acuity, increased outer retinal thickness, and improved photopic a- and b-wave responses compared with nontreated rd10 mice, treatment with SA4503 or PRE084 did not. The number of photoreceptor nuclei/100 µm retinal length in SA4503- and PRE084-treated rd10 mice (approximately 11/100) did not differ significantly from nontreated rd10 mice, whereas (+)-PTZ-treated mice had significantly more nuclei (approximately 22/100 µm). CONCLUSIONS: Cell survival and gene regulation experiments yielded similar outcomes when SA4503, PRE084, or (+)-PTZ were conducted in vitro, however neither SA4503 or PRE084 afforded in vivo protection in the severe rd10 retinopathy model comparable to (+)-PTZ. Despite all three compounds demonstrating the potential to activate sigma 1 receptor, the retinal neuroprotective properties of the three ligands differ significantly.
引用
- Wang J, Xiao H, Barwick SR, et al. Comparison of Sigma 1 Receptor Ligands SA4503 and PRE084 to (+)-Pentazocine in the rd10 Mouse Model of RP. Invest Ophthalmol Vis Sci. 2020. PMID: 33137196. doi:10.1167/iovs.61.13.3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。